Drug Profile
Research programme: antifungals - F2G/OncoTargeting/Pharmacelsus/Universities
Alternative Names: NOFUNLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator F2G
- Developer F2G; OncoTargeting; Pharmacelsus; Universitat Rovira i Virgili; University of Manchester
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Mycoses
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Mycoses in Germany
- 16 Jul 2016 No recent reports of development identified for research development in Mycoses in Spain
- 16 Jul 2016 No recent reports of development identified for research development in Mycoses in Sweden